ev3 Inc. Appoints John L. Miclot to Board of Directors

December 3, 2008

PLYMOUTH, Minn., Dec. 3 /PRNewswire-FirstCall/ — ev3 Inc. (Nasdaq: EVVV),
a global endovascular device company, today announced the appointment of John
L. Miclot
to its Board of Directors effective immediately.

Mr. Miclot is currently the president and chief executive officer of CCS
Medical, a privately held nationwide provider of various home care products
for chronic diseases such as diabetes, wound care, urology and respiratory
disorders. Prior to joining CCS Medical, Mr. Miclot served as chief executive
officer of Philips Home Healthcare Solutions from March 2008 until November
following the acquisition of Respironics, Inc. by Philips. From December
to March 2008, Miclot served as president and chief executive officer of
Respironics, Inc. Prior to that, Mr. Miclot served in various positions at
Respironics, Inc. from 1998 to 2003, including chief strategic officer and
president of the Homecare Division. Mr. Miclot joined Respironics in 1998
when it acquired Healthdyne Technologies where he had served as senior vice
president, sales and marketing from 1995 to 1998.

Mr. Miclot currently serves on the board of directors of Wright Medical
Group and several private companies including CCS Medical.

“We are delighted to have someone with John’s proven leadership skills and
extensive operational expertise join our board,” said Robert Palmisano,
president and chief executive officer of ev3. “John’s insight and experience
will be of great value as we work towards building the premier endovascular
company and preferred physician partner for identifying and treating
peripheral vascular and neurovascular disease.”

About ev3 Inc.

Since its founding in 2000, ev3 has been dedicated to developing
innovative, breakthrough and clinically proven technologies and solutions for
the treatment of peripheral vascular and neurovascular diseases. ev3′s
products are used by endovascular specialists to treat a wide range of
peripheral vascular and neurovascular diseases and disorders. The company
offers a comprehensive portfolio of treatment options, including the primary
interventional technologies used today — peripheral angioplasty balloons,
stents, plaque excision systems, embolic protection devices, liquid embolics,
embolization coils, thrombectomy catheters and occlusion balloons. More
information about the company and its products can be found at

ev3 and the ev3 logo are trademarks of ev3 Inc., registered in the U.S.
and other countries.

SOURCE ev3 Inc.

Source: newswire

comments powered by Disqus